Mary S Rosendahl
Overview
Explore the profile of Mary S Rosendahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez E, Ebata K, Randeria H, Rosendahl M, Cedervall E, Morales T, et al.
Blood
. 2023 Feb;
142(1):62-72.
PMID: 36796019
Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell-driven malignancies. However, approved covalent BTK inhibitors (cBTKis) are associated with treatment limitations because of off-target...
2.
Cox G, Lee J, Rosendahl M, Chlipala E, Doherty D
Protein J
. 2020 Mar;
39(2):160-173.
PMID: 32172395
Previously we reported that site-specific modification of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) A3C analog with polyethylene glycol (PEG) dramatically improved the pharmacokinetic properties of the protein in rats. However,...
3.
Rosendahl M, Doherty D, Smith D, Bendele A, Cox G
Bioprocess Int
. 2018 Jun;
3(4):52-60.
PMID: 29899681
No abstract available.
4.
Fam C, Eisenberg S, Carlson S, Chlipala E, Cox G, Rosendahl M
J Interferon Cytokine Res
. 2014 May;
34(10):759-68.
PMID: 24841172
Interferon gamma (IFN-γ) is a 28 kDa homodimeric cytokine that exhibits potent immunomodulatory, anti-proliferative, and antiviral properties. The protein is used to treat chronic granulomatous disease and malignant osteopetrosis, and...
5.
Lee J, Eisenberg S, Rosendahl M, Chlipala E, Brown J, Doherty D, et al.
J Interferon Cytokine Res
. 2013 Aug;
33(12):769-77.
PMID: 23962003
Interferon beta (IFN-β) is widely used to ameliorate disease progression in patients with Multiple Sclerosis. IFN-β has a short half-life in humans, necessitating frequent administration for optimum effectiveness. Covalent modification...
6.
Fradkin A, Boand C, Eisenberg S, Rosendahl M, Randolph T
Biotechnol Prog
. 2010 Mar;
26(3):743-9.
PMID: 20196161
We expressed recombinant murine growth hormone (rmGH) in E. coli as a cost-effective way to produce large quantities (gram scale) of the protein for use in murine studies of immunogenicity...
7.
Seefeldt M, Rosendahl M, Cleland J, Hesterberg L
Curr Pharm Biotechnol
. 2009 Jun;
10(4):447-55.
PMID: 19519422
Non-denaturing pressures of around 2000 bar are effective for eliminating and refolding protein aggregates and may be applicable in various phases of protein manufacturing to decrease aggregate levels in products...
8.
Bell S, Fam C, Chlipala E, Carlson S, Lee J, Rosendahl M, et al.
Bioconjug Chem
. 2007 Nov;
19(1):299-305.
PMID: 18020402
Recombinant interferon alpha-2 (IFN-alpha2) has proven useful for treating a variety of human cancers and viral diseases. IFN-alpha2 has a short circulating half-life in vivo, which necessitates daily or thrice...
9.
Cox G, Rosendahl M, Chlipala E, Smith D, Carlson S, Doherty D
Endocrinology
. 2007 Jan;
148(4):1590-7.
PMID: 17234711
Recombinant human GH is used to treat GH deficiency in children and adults and wasting in AIDS patients. GH has a circulating half-life of only a few hours in humans...
10.
Long D, Doherty D, Eisenberg S, Smith D, Rosendahl M, Christensen K, et al.
Exp Hematol
. 2006 May;
34(6):697-704.
PMID: 16728273
Objective: Erythropoietin (Epo) bioactivity is significantly reduced by modification of lysine residues with amine-reactive reagents, which are the most commonly used reagents for attaching polyethylene glycols (PEGs) to proteins to...